Live feed13:20:00·1150dPRReleasevia QuantisnowAvadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with NarcolepsyByQuantisnow·Wall Street's wire, on your screen.AVDL· Avadel Pharmaceuticals plcHealth Care
